Symplicity Spyral™ multi-electrode renal denervation system
DeviceAfter a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
Other names: Renal Angiography, Renal Denervation
NCT Number: NCT07115953
The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies in an uncontrolled hypertensive population.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
The Alfred Hospital, Melbourne, Australia
SPYRAL SWYFT will evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system to determine whether renal denervation performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective in reducing blood pressure than the procedural approach used in the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED clinical studies (where all accessible renal arterial vessels between 3 and 8 mm in diameter including accessory, branch and main renal arteries (outside the kidney parenchyma) were targeted for ablation).
SPYRAL SWYFT study is conducted under the overarching SPYRAL AFFIRM protocol (NCT05198674), focused on EU and APAC regions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After a renal angiography according to standard procedures, subjects are treated with the renal denervation procedure.
Other names: Renal Angiography, Renal Denervation
Time frame: Procedure
Procedure time will be compared to the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED procedure times.
Time frame: 6 months
Office Systolic Blood Pressure (OSBP) change from baseline to 6 months will be compared to the SPYRAL HTN-ON MED and SPYRAL PIVOTAL - SPYRAL HTN-OFF MED study efficacy endpoints using a propensity score stratified baseline blood pressure adjusted analysis at 3 months (OFF MED) and 6 months (ON MED).
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure
Time frame: Procedure to 36 months post-procedure
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure. A higher score means a better outcome.
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure
Time frame: From baseline to 3, 6, 12, 24, and 36 months post-procedure
Contact information is provided by the study sponsor or research team.
Carly Loudoun
CONTACT
Kelsey Anderson
CONTACT
Medtronic Vascular
Industry
Sub-study of SPYRAL AFFIRM: Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT)
Acronym: SWYFT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06907147
Cardiovascular Diseases, Chronic Disease
Stanford, California, United States
View Trial DetailsNCT05198674
Cardiovascular Diseases, Chronic Disease
Birmingham, Alabama, United States
View Trial DetailsNCT03987633
Arrhythmias, Cardiac, Arterial Occlusive Diseases
Wolverhampton, West Midlands, United Kingdom
View Trial DetailsNCT06239129
Acute Kidney Injury, Cardiovascular Diseases
View Trial Details